Carcinoma, Non-Small-Cell Lung

17 competing products in clinical development for Carcinoma, Non-Small-Cell Lung.

Pipeline by Phase

Pre-clinical1

Phase 13

Phase 1/23

Phase 28

Phase 32

All Products (17)

Product	Company	Stage	Status	Hype
Raludotatug Deruxtecan + Ifinatamab Deruxtecan + Docetetaxel + 5-hydroxytryptamine subtype 3 receptor antagonist + Neurokinin-1 receptor antagonist + Corticosteroid	Daiichi Sankyo	Phase 2	Recruiting	42
Tarceva (erlotinib HCl, OSI-774 )	Astellas Pharma	Phase 3	Completed	40
Pembrolizumab + Carboplatin + Paclitaxel + Pemetrexed + Vibostolimab + Boserolimab + MK-4830 + MK-0482 + Ifinatamab Deruxtecan (I-DXd) + HER3-DXd	Daiichi Sankyo	Phase 1/2	Recruiting	39
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	Recruiting	37
Datopotamab Deruxtecan (Dato-DXd)	Daiichi Sankyo	Phase 1/2	Active	36
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	Completed	35
LY2875358 + Erlotinib	Eli Lilly	Phase 2	Completed	35
ALIMTA + Carboplatin	Eli Lilly	Phase 2	Completed	35
Tarceva + carboplatin + paclitaxel	Astellas Pharma	Phase 2	Completed	35
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	Recruiting	32
Lazertinib	Yuhan	Phase 1/2	Completed	32
S-488410	Shionogi	Phase 2	UNKNOWN	31
Cetuximab	Eli Lilly	Phase 1	Completed	29
CS-7017 + Erlotinib	Daiichi Sankyo	Phase 1	Completed	29
CS-7017 + Carboplatin + Paclitaxel	Daiichi Sankyo	Phase 1	Completed	29
MORAb-202	Eisai	Phase 2	Terminated	27
Adjuvant	Insight Molecular Diagnostics	Pre-clinical	Terminated	8